Maitake MD-Fraction Mushroom Extract Therapy

To assist in the treatment of cancer, HIV, Hepatitis and Immune System Ddiseases.

Maitake: King of Mushrooms

Maitake (scientific name grifola frondosa) is indigenous to the northeastern part of Japan. In Japan, maitake can grow to more than 20 kilogram in size, earning it the title of King of Mushrooms. Maitake is so named not only for its large size but also for its amazing health benefits. Apart from the health benefits, it is also highly sought after for its excellent taste.

Medicinal mushroom-derived beta-glucans are notable for their ability to modulate the immune system. Sources of beta-glucan include various species of mushrooms, such as reishi, shiitake and maitake. Beta-glucans are known as “biological response modifiers” because of their ability to activate the immune system. Immunologists have discovered that receptors on the surface of innate immune cells called dectin-1 and complement receptor 3 (CR3 or CD11b/CD18) are responsible for binding to beta-glucans, allowing the immune cells to recognize them.

Maitake MD-Fraction – the original from Japan

Maitake beta-glucan MD-Fraction is the original patented product made to ISO standards in Japan.

Maitake Research

A phase I/II human trial, conducted by the Memorial Sloan–Kettering Cancer Center, showed maitake can stimulate the immune system of breast cancer patients. Small experiments with human cancer patients have shown that maitake can stimulate the immune system cells like NK cells. In vitro research has also shown that maitake can stimulate immune system cells, confirming the clinical experiments in humans.

Lesser studies with human cancer patients have revealed that the maitake D-fraction portion of the maitake mushroom is effective against cancer. In vitro research demonstrated that maitake has potential anti-metastatic properties. In 1997, the US Food and Drug Administration (FDA) approved an Investigational New Drug Application for a part of the mushroom.

Research has shown maitake has a hypoglycemic effect and may be beneficial in the management of diabetes. The reason maitake lowers blood sugar is due to the fact the mushroom contains a natural alpha glucosidase inhibitor. Alpha-glucosidase inhibitors are saccharides that act as competitive inhibitors of enzymes needed to digest carbohydrates. Since cancer cells have a preference for glucose, lowering blood sugar levels in cancer patients tends to produce beneficial effects for the patient. Clinical studies in cancer patients with Metformin, a common anti-diabetic drug, showed similar beneficial effects.

Maitake contains antioxidants and may partially inhibit the enzyme cyclooxygenase. An experiment showed that an extract of maitake inhibited angiogenesis via inhibition of the vascular endothelial growth factor (VEGF).


  • The High-Dose Maitake MD-Fraction is 400 mg (2 capsules taken twice daily) about 30 minutes before breakfast and dinner.
  • The Moderate-Dose Maitake MD-Fraction is 200 mg (1 capsule taken twice daily) about 30 minutes before breakfast and dinner.
  • Side effects are not common but for people experiencing a mild stomach disorder, it is recommended to start with a lower dose or take it with a small amount of food, or at the beginning or end of a meal.


  • Deng G., Lin H., Seidman A., et al. (2009). ” Phase I/II Trial of a Polysaccharide Extract From Grifola Frondosa (Maitake Mushroom) in Breast Cancer Patients: Immunological Effects”. Journal of Cancer Research and Clinical Oncology. 135 (9): 1215–21.
  • Kodama N., Komuta K., Nanba H. (2003). “Effect of Maitake (Grifola Frondosa) D-Fraction on the Activation of NK Cells In Cancer Patients”. Journal of Medicinal Food. 6 (4): 371–7.
  • Kodama N., Komuta K., Sakai N., Nanba H. (2002). “Effects of D-Fraction, a Polysaccharide From the Grifola Frondosa on Tumor Growth Involves Acti-vation of NK Cells”. Biological & Pharmaceutical Bulletin. 25 (12): 1647–50.
  • Kodama N, Asakawa A, Inui A, Masuda Y, Nanba H (2005). “Enhancement of Cytotoxicity of NK Cells By D-Fraction, A Polysaccharide from Grifola Frondosa”. Oncology Reports. 13 (3): 497–502.
  • Kodama N, Komuta K, Nanba H (2002). “Can the Maitake MD-Fraction Aid Cancer Patients?” Alternative Medicine Review. 7 (3): 236–9.
  • Nanba H., Kubo K. (1997). “Effect of Maitake D-Fraction on Cancer Prevention”. Annals of The New York Academy of Sciences. 833 (1 Cancer): 204–7.
  • Masuda Y., Murata Y., Hayashi M., Nanba H. (2008). “Inhibitory Effect of MD-Fraction on Tumor Metastasis: Involvement of NK Cell Activation and Suppression of Intercellular Adhesion Molecule (ICAM)-1 Expression in Lung Vascular Endothelial Cells”. Biological & Pharmaceutical Bulletin. 31 (6): 1104–8.
  • Konno S., Tortorelis DG., Fullerton SA., Samadi AA., Hettiarachchi J., Tazaki H. (2001). “A Possible Hypoglycaemic Effect of Maitake Mushroom on Type 2 Diabetic Patients”. Diabetic Medicine. 18 (12): 1010.
  • Hong L., Xun M., Wutong W. (2007). “Anti-Diabetic Effect of an Alpha-Glucan from Fruit Body of Maitake (Grifola Frondosa) on KK-Ay Mice”. Journal of Pharmacy and Pharmacology. 59 (4): 575–82.
  • Kubo K., Aoki H., Nanba H. (1994). “Anti-Diabetic Activity Present in the Fruit Body of Grifola Frondosa (Maitake). I”. Biological & Pharmaceutical Bulletin. 17 (8): 1106–10.
  • Lo HC, Hsu TH, Chen CY (2008). “Submerged Culture Mycelium and Broth of Grifola Frondosa Improve Glycemic Responses In Diabetic Rats”. American Journal of Chinese Medicine. 36 (2): 265–85.
  • Manohar V, Talpur NA, Echard BW, Lieberman S, Preuss HG (2002). “Effects of a Water-Soluble Extract of Maitake Mushroom on Circulating Glucose/Insulin Concentrations In KK Mice”. Diabetes, Obesity and Metabolism. 4 (1): 43–8.
  • Horio H, Ohtsuru M (2001). “Maitake (Grifola Frondosa) Improve Glucose Tolerance of Experimental Diabetic Rats”. Journal of Nutritional Science and Vitaminology. 47 (1): 57–63.
  • Matsuru H., Asakawa C., Kurimoto M., Mizutani J. (2002). “Alpha-Glucosidase Inhibitor From the Seeds of Balsam Pear (Momordica Charantia) and the Fruit Bodies of Grifola Frondosa”. Bioscience, Biotechnology and Biochemistry. 66 (7): 1576–8.
  • Zhang Y., Mills Gl., Nair Mg. (2002). “Cyclooxygenase Inhibitory and Antioxidant Compounds From the Mycelia of the Edible Mushroom Grifola Frondosa”. Journal of Agricultural and Food Chemistry. 50 (26): 7581–5.
  • Lee JS., Park BC., Ko YJ. et al. (2008). “Grifola Frondosa (Maitake Mushroom) Water Extract Inhibits Vascular Endothelial Growth Factor-Induced Angio-genesis Through Inhibition of Reactive Oxygen Species and Extracellular Signal-Regulated Kinase Phosphorylation”. Journal of Medicinal Food. 11 (4): 643–51.
  • Lin H., She YH., Cassileth BR., Sirotnak F., Cunningham Rundles S. (2004) “Maitake Beta-Glucan MD-Fraction Enhances Bone Marrow Colony Formation and Reduces Doxorubicin Toxicity In Vitro”.
  • Wasser, SP.; Weis AL. (1999). “Therapeutic Effects of Substances Occurring in Higher Basidiomycetes Mushrooms: A Modern Perspective”. Critical Reviews In Immunology. (United States: Begell House) 19 (1): 65–96.
  • Miura, NN.; Ohno N., Aketagawa J., Tamura H., Tanaka S., Yadomae T. (1996). “Blood Clearance of (1–>3)-Beta-D-Glucan in MRL Lpr/Lpr Mice”. FEMS Immunology and Medical Microbiology. (England: Blackwell Publishing) 13 (1): 51–57.
  • Brown, GD; Gordon, S (2001). “Immune Recognition. A New Receptor for Beta-Glucans”. Nature. 413 (6851): 36–7.
  • Vetvicka, V.; Dvorak B., Vetvickova J., Richter J., Krizan J., Sima P., Yvin JC. (2007). “Orally Administered Marine (1?3)-Beta-D-Glucan Phycarine Stimu-lates Both Humoral and Cellular Immunity”. International Journal of Biological Macromolecules. (England: Butterworth-Heinemann) 40 (4): 291–298.